Skip to content 
Right now, in pharmaceuticals, a booming business opportunity is waiting for you as fexofenadine montelukast tablets manufacturers in India are appointing PCD Pharma Franchise partners. This is an incredibly lucrative and sustainable opportunity for new and existing franchise owners. In India, anti-allergic and anti-inflammatory medicines are considered to be a must-have item in a franchise product portfolio to effectively meet the dynamic market demand of pharmaceuticals. This is why acquiring monopoly franchise rights for fexofenadine montelukast tablets is an easy-to-run business opportunity that all franchise owners should consider.
Market demand and value of Fexofenadine Montelukast Tablets in India
Fexofenadine Montelukast tablets are used to treat short-term allergic reactions such as persistent sneezing, watery eyes, redness, and difficulty breathing. These symptoms emerge from rhinitis and other seasonal allergies. In India, due to heavy pollution and seasonal changes, millions of people suffer from allergic reactions. From allergic bronchitis to hay fever and allergic rhinitis to sudden allergies, a large population of Indians consume anti-allergic medicines such as fexofenadine montelukast tablets. Due to this heavy consumption and demand for anti-allergic tablets, fexofenadine montelukast tablets have a great market share regarding economic benefits. These particular tablets have great potential for franchising and other businesses due to high demand and value addition in healthcare markets.
PCD pharma franchise opportunities with Fexofenadine 120 mg + Montelukast 10 mg tablets
As we mentioned above, the demand and consumption of fexofenadine montelukast tablets are very high in India. These tablets, considered in tandem, are a good value product for franchising businesses. When a franchise partner curates a product portfolio, it is highly recommended to include a small range of antiallergic medicines to satisfy the market and healthcare demand for such specific products. These tablets have a good prescription rate as per market records, and year-long allergies ensure their regular business flow without any dip in revenue generation. This is why these tablets are considered one of the vital elements in a PCD Pharma Franchise product portfolio for PAN-India franchise partners.
Benefits of franchising with fexofenadine montelukast tablets in India:-
- High prescription rate
Exceptionally high prescription rate of combination therapy drives sales volume, helping franchise partners achieve faster growth and profitability.
- Strong doctor preference Doctors in India regularly prescribe this formulation to treat allergies. This increases repeat orders, ensuring consistent monthly revenue and reducing dependency on aggressive marketing or heavy promotional spending.
- Attractive profit margins
Anti-allergic tablets always have additional profitability potential and better returns per unit, making them a high-molecule product for franchising.
- Wide patient base
Millions of Indians, suffer from allergies and asthma ensure broader market reach, directly contributing to higher sales potential across urban and rural areas.
- Faster inventory turnover
Fast moving molecules minimizes expiry risks, allowing franchise owners to maintain lean stock while maximizing return on investment efficiently.
- Seasonal demand spikes During allergy seasons like late summer, monsoon, and winter, fexofenadine montelukast tablet demand instantly rises, offering great potential for enhanced business for franchise partners.
- Monopoly rights
Companies offer monopoly-based distribution and franchise privileges in assigned territory to reduce competition, enabling better pricing control and higher sales conversion rates for franchise distributors.
Join India’s Best Fexofenadine Montelukast Tablets Manufacturers
We are proud to introduce India’s best fexofenadine montelukast tablets manufacturers: Sanes Pharmaceuticals.
Sanes is an ideal pharmaceutical manufacturing company that produces WHO-GMP certified and international quality medicines. This company also falls into the category of top franchise providers in India. Right now, Sanes is manufacturing and supplying its own fexofenadine montelukast tablets, ZENECET-FX (Fexofenadine 120 mg + Montelukast 10 mg). This particular tablet is the best franchising product in PAN-INDIA healthcare markets. Records state that this is the highest revenue-generating molecule for PAN-India franchise partners. Therefore, this is your opportunity to invest in this product, include it in your product portfolio, and significantly increase your direct profitability in pharmaceuticals. Hence, join Sanes, India’s top and doctors’ preferred brand for quality medicines.
